相关概念视频
Drug Discovery: Overview
12.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.5K
Uncertainty: Overview
1.8K
In analytical chemistry, we often perform repetitive measurements to detect and minimize inaccuracies caused by both determinate and indeterminate errors. Despite the cares we take, the presence of random errors means that repeated measurements almost never have exactly the same magnitude. The collective difference between these measurements - observed values - and the estimated or expected value is called uncertainty. Uncertainty is conventionally written after the estimated or expected value.
1.8K
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
48
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
48
Pharmacodynamic Models: Overview
54
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
54
Pharmacogenomics: Identification of New Drug Targets
55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
您也可能阅读
相关文章
通过共同作者、期刊和引用图与本文相关的文章。
排序
Same author
Smart battery management in EVs using IoT, blockchain, and machine learning.
Scientific reports·2025
不确定性意识的混合深度生成框架,用于强大的和可解释的药物发现.
Saniya Gupta1, A Sherly Alphonse2, D Kavitha1
1School of Computer Science and Engineering, Vellore Institute of Technology, Chennai, Chennai, India.
BMC bioinformatics
|March 4, 2026
概括
这项研究引入了一种用于药物发现的新型AI框架,以提高精度和可靠性来增强分子生成. 它解决了关键的挑战,加速了新药的开发.
科学领域:
- 计算化学是一种计算化学.
- 人工智能在药物发现中的作用
- 机器学习用于分子设计.
背景情况:
- 由于巨大的化学空间和固有的不确定性,传统的药物发现是缓慢而昂贵的.
- 目前的AI/ML方法面临着诸如高消耗率和同时优化多个分子性质等挑战.
- 需要强大的和可解释的方法来提高早期药物发现效率.
研究的目的:
- 开发一种混合计算框架,用于生成具有所需药理性质的新药分子.
- 通过整合不确定性意识和可解释性来解决现有方法的局限性.
- 为了提高可靠性和减少人工智能驱动的候选药物产生的假阳性.
主要方法:
- 集成图形卷积网络,变化自编码器和不确定性意识的基于多目标优化的自适应强化学习 (UAAMOO-RL).
- 根据ChEMBL数据集 (150万个生物活性分子) 进行培训和验证的框架.
- 纳入不确定性意识和可解释性,用于强大的分子生成.
主要成果:
- 在0.60.6的门下,在ChEMBL数据集上实现了88.8%的定量药物相似性 (QED) 通过率.
- 在保持多样性,独特性和有效性的同时,在分子生成中超越了最先进的技术.
- 在Zinc250k (82.7%) 和PDBbind (85.9%) 数据集上显示出显著的改进.
结论:
- 新的混合AI框架有效地产生可靠和可解释的药物分子.
- 这种方法通过减少对广泛实验查的需求,显著提高了早期药物发现的效果.
- 该方法为现代药物开发中的关键挑战提供了强有力的解决方案,提高了效率和成功率.

